Literature DB >> 2183997

Drugs that alter blood viscosity. Their role in therapy.

A M Ehrly1.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2183997     DOI： 10.2165/00003495-199039020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  14 in total

1.  SERUM PROTEIN DISORDERS CAUSING CLINICAL SYMPTOMS IN MALIGNANT NEOPLASTIC DISEASE.

Authors:  J L FAHEY
Journal:  J Chronic Dis       Date:  1963-07

2.  Rheomacrodex--a new dextran solution for rheological treatment of impaired capillary flow.

Authors:  L E GELIN; B INGELMAN
Journal:  Acta Chir Scand       Date:  1961-11

3.  Altered deformability of erythrocytes from patients with chronic occlusive arterial disease.

Authors:  A M Ehrly; H J Köhler
Journal:  Vasa       Date:  1976       Impact factor: 1.961

4.  [Short-term fibrinolytic treatment in acute myocardial infarction].

Authors:  K Breddin; A M Ehrly; L Fechler; D Frick; H König; H Kraft; H Krause; H J Krzywanek; J Kutschera; H W Lösch; O Ludwig; B Mikat; F Rausch; P Rosenthal; S Sartory; G Voigt; P Wylicil
Journal:  Dtsch Med Wochenschr       Date:  1973-04-27       Impact factor: 0.628

5.  [Improvement of flow properties of blood: a new principle for drug therapy of chronic peripheral arterial vascular disorders].

Authors:  A M Ehrly
Journal:  Vasa Suppl       Date:  1973

6.  Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise.

Authors:  A M Ehrly; K Saeger-Lorenz
Journal:  Angiology       Date:  1987-02       Impact factor: 3.619

7.  Impaired red cell deformability in peripheral vascular disease.

Authors:  H L Reid; J A Dormandy; A J Barnes; P J Lock; T L Dormandy
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

8.  Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients.

Authors:  J M Porter; B S Cutler; B Y Lee; T Reich; F A Reichle; J T Scogin; D E Strandness
Journal:  Am Heart J       Date:  1982-07       Impact factor: 4.749

9.  Amelioration of blood viscosity in sickle cell anemia by pentoxifylline. A case report.

Authors:  F Keller; H Leonhardt
Journal:  J Med       Date:  1979

Review 10.  Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.

Authors:  S P Clissold; S Lynch; E M Sorkin
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546
View more
  4 in total

Review 1.  Alcoholic steatohepatitis: management and prognosis.

Authors:  Jacquelyn J Maher
Journal:  Curr Gastroenterol Rep       Date:  2007-03

2.  Band 3 antagonists, p-azidobenzylphlorizin and DIDS, mediate erythrocyte shape and flexibility changes as characterized by digital image morphometry and microfiltration.

Authors:  D M Hoefner; M E Blank; B M Davis; D F Diedrich
Journal:  J Membr Biol       Date:  1994-07       Impact factor: 1.843

3.  Effects of pentoxifylline on equine neutrophil function and flow properties.

Authors:  D J Weiss; R J Geor; S M Burris; C M Smith
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

4.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.